Biophytis its participation in the 17th edition of the SCWD Congress (Society on Sarcopenia, Cachexia & Wasting Disorders), taking place from December 6 to 8, 2024, in Washington, D.C.
As part of the congress, Biophytis will host an Obesity Investor Call on the topic: “GLP-1 RA weight loss therapy-induced muscle loss: A medical need to explore?”. The panel of experts will feature key opinion leaders in clinical and medical research:
- Professor Roger Fielding, Professor of Nutrition and Medicine, Tufts University
- Professor Marc André Cornier, Endocrinologist, Medical University of South Carolina
- Professor William Evans, Associate Professor of Human Nutrition, University of California,
Berkeley
This session will provide participants with a deeper understanding of the clinical implications and potential therapeutic solutions to counter the side effects of GLP-1 RA obesity treatments.
Stanislas Veillet, CEO and Founder of Biophytis, will present the company’s strategic positioning in this field, and the session will be moderated by Rob Van Maanen, Chief Medical Officer of Biophytis.
The event will take place on Friday, December 6, at 12:45 PM ET (6:45 PM CET). Analysts and investors can register and join the event remotely via this link: https://uptownevents-co-
uk.zoom.us/webinar/register/WN_HfHAmCayQ76gcpFw9MGT6Q